Molecular structure of Acalabrutinib, CAS Number: 1420477-60-6
Acalabrutinib (CAS 1420477-60-6)
CAS Number:
1420477-60-6
Molecular Weight:
465.5
Molecular Formula:
C26H23N7O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Acalabrutinib (CAS 1420477-60-6) References
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. | Byrd, JC., et al. 2016. N Engl J Med. 374: 323-32. PMID: 26641137
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. | Wang, M., et al. 2018. Lancet. 391: 659-667. PMID: 29241979
- Acalabrutinib for mantle cell lymphoma. | Witzig, TE. and Inwards, D. 2019. Blood. 133: 2570-2574. PMID: 30967367
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. | Sharman, JP., et al. 2020. Lancet. 395: 1278-1291. PMID: 32305093
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. | Ghia, P., et al. 2020. J Clin Oncol. 38: 2849-2861. PMID: 32459600
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. | Byrd, JC., et al. 2021. J Clin Oncol. 39: 3441-3452. PMID: 34310172
- Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. | Sharman, JP., et al. 2022. Leukemia. 36: 1171-1175. PMID: 34974526
- Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. | Ghia, P., et al. 2022. Hemasphere. 6: e801. PMID: 36398134
- Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. | Seymour, JF., et al. 2023. Blood. 142: 687-699. PMID: 37390310
Inhibitor of:
3100002L24Rik, ASCL4, B Cell Marker, Btk, CD45, CD79A, DLD, Ear10, Gight chain, HACS1, IFN-β, Ig κ, Ig λ, Ig λ chain, Ig λ chain V4A, IgD Chain, IgH, Igk-C, LAX1, MALT1, Mig12, MLSN1, MUM1, Myosin-XVA, Olr113, Olr1156, Olr1206, Olr1245, Olr168, Olr170, Olr184, Olr309, Olr530, Olr655, Olr659, Olr714, Olr734, OTTMUSG00000005931, Pinch-2, PKC ζ, Protein tyrosine phosphatase receptor (PTPR), PTPκ, RAG-1, Shank 3, TNF receptor superfamily (TNFRSF), Trav12d-3, TRIL, and VpreB1.Activator of:
BCMP1, Bcr, Bu-1a, CD19, IBtk, and Tec.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Acalabrutinib, 250 mg | sc-507392 | 250 mg | $255.00 |